Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 260

1.

Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.

O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ.

Cancer Res. 2013 Jun 1;73(11):3356-70. doi: 10.1158/0008-5472.CAN-12-3904. Epub 2013 Apr 10.

PMID:
23576564
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.

Simara P, Stejskal S, Koutna I, Potesil D, Tesarova L, Potesilova M, Zdrahal Z, Mayer J.

Am J Hematol. 2013 May;88(5):385-93. doi: 10.1002/ajh.23419. Epub 2013 Mar 27.

PMID:
23420553
[PubMed - indexed for MEDLINE]
3.

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.

Oncotarget. 2012 Dec;3(12):1557-65.

PMID:
23238683
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.

Lipka DB, Wagner MC, Dziadosz M, Schnöder T, Heidel F, Schemionek M, Melo JV, Kindler T, Müller-Tidow C, Koschmieder S, Fischer T.

PLoS One. 2012;7(7):e40853. doi: 10.1371/journal.pone.0040853. Epub 2012 Jul 16.

PMID:
22815843
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.

Clin Cancer Res. 2006 Oct 1;12(19):5869-78.

PMID:
17020995
[PubMed - indexed for MEDLINE]
Free Article
6.

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A.

Mol Oncol. 2013 Dec;7(6):1103-15. doi: 10.1016/j.molonc.2013.08.006. Epub 2013 Aug 22.

PMID:
24012109
[PubMed - indexed for MEDLINE]
Free Article
7.

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.

Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R.

Cancer Res. 2008 Dec 1;68(23):9624-33. doi: 10.1158/0008-5472.CAN-08-1131.

PMID:
19047139
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Suppression of autophagy by BCR/ABL.

Calabretta B, Salomoni P.

Front Biosci (Schol Ed). 2012 Jan 1;4:453-60. Review.

PMID:
22202070
[PubMed - indexed for MEDLINE]
9.

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.

Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW.

Blood. 2009 Oct 15;114(16):3459-63. doi: 10.1182/blood-2007-10-113969. Epub 2009 Aug 25.

PMID:
19706883
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG.

J Hematol Oncol. 2011 Feb 7;4:6. doi: 10.1186/1756-8722-4-6.

PMID:
21299849
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.

Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11.

PMID:
24629639
[PubMed - indexed for MEDLINE]
12.

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B.

J Clin Invest. 2009 May;119(5):1109-23. doi: 10.1172/JCI35660. Epub 2009 Apr 13. Erratum in: J Clin Invest. 2013 Aug 1;123(8):3634.

PMID:
19363292
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.

Lee J, Shen P, Zhang G, Wu X, Zhang X.

Biomed Pharmacother. 2013 Mar;67(2):157-63. doi: 10.1016/j.biopha.2012.10.017. Epub 2012 Nov 19.

PMID:
23201011
[PubMed - indexed for MEDLINE]
14.

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.

Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T.

Leukemia. 2013 Jan;27(1):118-29. doi: 10.1038/leu.2012.222. Epub 2012 Aug 3.

PMID:
22858987
[PubMed - indexed for MEDLINE]
15.

Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.

Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.

Clin Cancer Res. 2014 Jan 1;20(1):151-63. doi: 10.1158/1078-0432.CCR-13-1063. Epub 2013 Dec 12.

PMID:
24334603
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.

Cancer Lett. 2014 Jun 28;348(1-2):50-60. doi: 10.1016/j.canlet.2014.03.012. Epub 2014 Mar 18.

PMID:
24657654
[PubMed - indexed for MEDLINE]
17.

Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.

Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM.

Blood. 2012 Mar 8;119(10):2335-45. doi: 10.1182/blood-2011-06-361261. Epub 2012 Jan 18.

PMID:
22262776
[PubMed - indexed for MEDLINE]
Free Article
18.

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.

Wu N, Kurosu T, Oshikawa G, Nagao T, Miura O.

Int J Oncol. 2013 Feb;42(2):419-28. doi: 10.3892/ijo.2012.1729. Epub 2012 Dec 6.

PMID:
23233201
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.

Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL.

Cancer Cell. 2008 Dec 9;14(6):485-93. doi: 10.1016/j.ccr.2008.11.001.

PMID:
19061839
[PubMed - indexed for MEDLINE]
Free Article
20.

The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors.

Glowacki S, Synowiec E, Blasiak J.

Int J Mol Sci. 2013 Aug 7;14(8):16348-64. doi: 10.3390/ijms140816348.

PMID:
23965958
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk